A novel smad3 splice variant as a target in chronic renal failure, atherosclerosis and fibrosis
CA 2238670 A1 · Owner: Laping, Nicholas · Inventors: Zhu, Yuan; Laping, Nicholas
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
sMAD3d polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing sMAD3d polypeptides and polynucleotides in the design of protocols for the treatment of chronic renal failure atherosclerosis, and fibrosis, among others and diagnostic assays for such conditions.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 24, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 24, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 24, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.